Thomas William LeBlanc, MD

Associate Professor of Medicine
Associate Professor in Population Health Sciences
Member of the Duke Cancer Institute
Campus mail 2424 Erwin Road, Suite 602, Durham, NC 27705
Phone (919) 668-2115
Email address thomas.leblanc@duke.edu

I am a medical oncologist, palliative care physician, and patient experience researcher.  My clinical practice focuses on the care of patients with hematologic malignancies, with a particular emphasis on myeloid conditions and acute leukemias including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs / MPDs, CML).  

As founding Director of the Duke Cancer Patient Experience Research Program (CPEP), my research investigates common issues faced by people with cancer, including issues of symptom burden, quality of life, psychological distress, prognostic understanding, and treatment decision-making. This work aims to improve patients' experiences living with serious illnesses like blood cancers, including the integration of specialist palliative care services to provide an extra layer of support along with their comprehensive cancer care. More broadly, our team in CPEP conducts various studies of patient experience and outcomes issues in oncology, including retrospective chart review studies, comparative effectiveness work, prospective observational studies and registries, and qualitative research, along with efforts to facilitate the integration of patient-generated health data (PGHD) into routine cancer care processes, such as with electronic patient-reported outcome measures (ePROs) and other mobile health interventions (mHealth). 

This work has led to recognition as an "Inspirational Leader under 40" by the American Academy of Hospice and Palliative Medicine (AAHPM), "Fellow" status from the Academy in 2016, the 2018 international "Clinical Impact Award" from the European Association for Palliative Care, and the AAHPM "Early Career Investigator" award in 2020. I served as 2017-18 Chair of the ASCO Ethics Committee, and currently Chair the Scientific Review Committee of the NIH/NINR-funded Palliative Care Research Cooperative Group (PCRC; www.palliativecareresearch.org). I have served on various national guideline panels for AML and for palliative/supportive care issues in oncology, and was inducted as a Fellow of the American Society of Clinical Oncology (FASCO) in 2021. To date I have published over 150 Medline-indexed articles, and several chapters in prominent textbooks of oncology and palliative medicine.

Education and Training

  • Fellow, Medical Oncology, Duke University School of Medicine, 2012 - 2013
  • Fellowship, Hospice And Palliative Medicine, Duke University School of Medicine, 2011 - 2012
  • Chief Medical Resident, Duke University School of Medicine, 2010 - 2011
  • Resident, Duke University School of Medicine, 2007 - 2009
  • Intern, Duke University School of Medicine, 2006 - 2007
  • M.D., Duke University, 2006

Publications

Navari, Rudolph M., Gary Binder, Eric J. Roeland, Alexander Molassiotis, Kathryn J. Ruddy, Thomas W. LeBlanc, Dwight D. Kloth, et al. “Duration of chemotherapy-induced nausea and vomiting (CINV) as a predictor of later-cycle CINV.” In Cancer Research, Vol. 81, 2021.

Scholars@Duke

Navari, Rudolph M., Gary Binder, Alexander Molassiotis, Eric Roeland, Kathryn J. Ruddy, Thomas W. LeBlanc, Dwight D. Kloth, et al. “Chemotherapy-induced nausea and vomiting (CINV) risk after prior breakthrough CINV: Unmasking the false average.” In Cancer Research, Vol. 81, 2021.

Scholars@Duke

Nelson, A. M., H. L. Amonoo, A. R. Kavanaugh, J. A. Webb, V. A. Jackson, J. Rice, M. W. Lavoie, et al. “Palliative care and coping in patients with acute myeloid leukemia: Mediation analysis of data from a randomized clinical trial.” In Cancer, 2021. https://doi.org/10.1002/cncr.33886.

Full Text

Rao, Vinay B., Emmanuelle Belanger, Pamela C. Egan, Thomas W. LeBlanc, and Adam J. Olszewski. “Early Palliative Care Services and End-of-Life Care in Medicare Beneficiaries with Hematologic Malignancies: A Population-Based Retrospective Cohort Study.” J Palliat Med 24, no. 1 (January 2021): 63–70. https://doi.org/10.1089/jpm.2020.0006.

PMID
32609039
Full Text

Shah, Anne, Allison Petrilla, Mayvis Rebeira, Joseph Feliciano, Julie Lisano, and Thomas W. LeBlanc. “Health Care Resource Utilization and Costs Among Medicare Beneficiaries Newly Diagnosed With Peripheral T-cell Lymphoma: A Retrospective Claims Analysis.” Clin Lymphoma Myeloma Leuk 21, no. 1 (January 2021): e1–9. https://doi.org/10.1016/j.clml.2020.07.011.

PMID
33184000
Full Text

Le, Hannah, Kellie Ryan, Svea K. Wahlstrom, Martine C. Maculaitis, Oliver Will, Emily Mulvihill, and Thomas W. LeBlanc. “Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects.” Patient Prefer Adherence 15 (2021): 99–110. https://doi.org/10.2147/PPA.S289139.

PMID
33519195
Full Text

Chang, Yaping, Gordon H. Guyatt, Trevor Teich, Jamie L. Dawdy, Shaneela Shahid, Jessica K. Altman, Richard M. Stone, et al. “Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review.” Plos One 16, no. 3 (2021): e0249087. https://doi.org/10.1371/journal.pone.0249087.

PMID
33784346
Full Text

Loh, Kah Poh, Mazie Tsang, Thomas W. LeBlanc, Anthony Back, Paul R. Duberstein, Supriya Gupta Mohile, Ronald M. Epstein, et al. “Decisional involvement and information preferences of patients with hematologic malignancies.” Blood Adv 4, no. 21 (November 10, 2020): 5492–5500. https://doi.org/10.1182/bloodadvances.2020003044.

PMID
33166406
Full Text

Pabon, Cindy M., Zhiguo Li, Therese Hennig, Carlos De Castro, Jadee Neff, Mitchell E. Horwitz, Thomas W. Leblanc, et al. “Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant.” In Blood, 136:24–25. American Society of Hematology, 2020. https://doi.org/10.1182/blood-2020-133901.

Full Text

Pages